Literature DB >> 31317515

Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas.

Silvana Novelli1, Anna Monter2, M Pilar García-Muret3, Rodrigo Martino2, Javier Briones2, Jorge Sierra2.   

Abstract

Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

Entities:  

Keywords:  Allogeneic hematopoietic transplantation; Cutaneous T cell lymphoma; Mycosis fungoide; Sézary syndrome

Mesh：

Year:  2019        PMID： 31317515     DOI： 10.1007/s12185-019-02707-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

Authors:  B Vergier; A de Muret; M Beylot-Barry; L Vaillant; D Ekouevi; G Chene; A Carlotti; N Franck; P Dechelotte; P Souteyrand; P Courville; P Joly; M Delaunay; M Bagot; F Grange; S Fraitag; J Bosq; T Petrella; A Durlach; A De Mascarel; J P Merlio; J Wechsler
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rafael F Duarte; Carmen Canals; Francesco Onida; Ian H Gabriel; Reyes Arranz; William Arcese; Augustin Ferrant; Guido Kobbe; Franco Narni; Giorgio Lambertenghi Deliliers; Eduardo Olavarría; Norbert Schmitz; Anna Sureda
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

4.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Authors:  Youn H Kim; Howard L Liu; Serena Mraz-Gernhard; Anna Varghese; Richard T Hoppe
Journal:  Arch Dermatol       Date:  2003-07

5.  Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines.

Authors:  Takaaki Kondo; Masafumi Takiguchi
Journal:  Int Immunol       Date:  2009-03-04       Impact factor: 4.823

6.  High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma.

Authors:  S Ingen-Housz-Oro; H Bachelez; O Verola; C Lebbé; J P Marolleau; C Hennequin; L Dubertret; P Morel; C Gisselbrecht; P Brice
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

7.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

Authors:  Maria Grazia Bernengo; Pietro Quaglino; Alessandra Comessatti; Michela Ortoncelli; Mauro Novelli; Francesco Lisa; Maria Teresa Fierro
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

8.  Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.

Authors:  Suzanne O Arulogun; H Miles Prince; Jonathan Ng; Stephen Lade; Gail F Ryan; Odette Blewitt; Christopher McCormack
Journal:  Blood       Date:  2008-07-22       Impact factor: 22.113

Review 9.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Authors:  Elise Olsen; Eric Vonderheid; Nicola Pimpinelli; Rein Willemze; Youn Kim; Robert Knobler; Herschel Zackheim; Madeleine Duvic; Teresa Estrach; Stanford Lamberg; Gary Wood; Reinhard Dummer; Annamari Ranki; Gunter Burg; Peter Heald; Mark Pittelkow; Maria-Grazia Bernengo; Wolfram Sterry; Liliane Laroche; Franz Trautinger; Sean Whittaker
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.